NOT FDA-APPROVED

Epithalon (Epitalon)

A four-amino-acid peptide developed in Russia and tested for decades in longevity research. Famous for the headline that it might activate telomerase, the enzyme that maintains the protective caps on chromosomes.

The 30-second read

Epithalon is a tiny synthetic peptide, just four amino acids, derived from a pineal-gland extract studied since the 1970s by V. Khavinson and his team in St. Petersburg. It's the peptide most often cited in conversations about telomere biology and longevity, because Russian studies have reported that it activates telomerase (the enzyme that maintains chromosome caps as cells divide). The animal data is consistent and the human data is suggestive, but almost all of it comes from one research group, and Western replication has been limited. It's not FDA-approved. The mechanism is plausible enough to take seriously and the source-bias issues are big enough to take seriously too.

Why this peptide is on people's radar

Epithalon comes from one of the more unusual research stories in modern peptide science. Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology spent decades isolating and synthesizing peptides from organ extracts, including a pineal-gland extract called Epithalamin. Epithalon is the synthetic four-amino-acid sequence (Ala-Glu-Asp-Gly) they identified as the active core. They've published animal lifespan-extension data, human trials in elderly patients reporting biomarker improvements, and mechanistic work suggesting telomerase activation.

The longevity-research and biohacking communities pulled Epithalon out of the Russian literature into broader awareness. Bryan Johnson-style protocols, longevity clinics, and the "Anti-Aging Stack" conversation in podcast circles all bring it up. The pitch is straightforward: if there's a peptide that might genuinely slow biological aging at the cellular level, this is the one with the longest research track record behind it.

The honest backdrop: most of the published research is in Russian-language journals, conducted by one institute, and not independently replicated by Western groups at scale. That doesn't make it wrong, but it does mean the evidence picture is different from drugs that have been put through the modern FDA-style trial pipeline.

What people are usually trying to do with it

People exploring Epithalon are usually focused on:

  • Supporting cellular and biological aging at the telomere level
  • Improving sleep quality (the pineal-gland origin links it to circadian and melatonin systems)
  • Restoring more youthful patterns in pituitary and adrenal hormones
  • Adding a peptide with a long research history to a broader longevity protocol
  • Exploring the cellular-aging side of the longevity conversation alongside diet, exercise, and sleep

What the science actually shows

The published research is more substantial than skeptics often acknowledge, and more concentrated in one source than enthusiasts often acknowledge. Plain-English summary:

Telomerase activation

In-vitro studies report that Epithalon can activate telomerase in human cell cultures, lengthening telomeres in dividing cells. Mechanism is not fully characterized.12

Animal lifespan extension

Multiple Russian studies report increased lifespan in mice, rats, and fruit flies treated with Epithalon, particularly in tumor-prone strains. Effect sizes are modest but consistent in the published literature.3

Sleep and circadian markers

Trials in elderly patients have reported improvements in sleep quality and night-time melatonin secretion patterns, consistent with a pineal-axis effect.4

Cardiovascular and metabolic markers

Russian human trials have reported improvements in blood pressure, lipid markers, and glucose tolerance in elderly populations. Studies are open-label, smaller, and not blinded by Western RCT standards.5

Replication and reproducibility

Most of the published work originates from V. Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology. Independent replication outside that institute is limited. Western biotech has not pursued Epithalon for clinical development.

The honest read

What's solid:

Decades of research, a coherent mechanistic story, animal data showing lifespan extension, and human pilot data suggesting biomarker improvements. For a longevity peptide, this is one of the more substantial evidence files.

What's still unproven:

Almost all the published work comes from one research institute. Independent Western replication is limited. The clinical-trial standards used in much of the original research are not equivalent to modern FDA-style RCTs. Whether the telomerase-activation effect translates into clinically meaningful longevity outcomes in healthy humans has not been established.

What's hyped beyond the evidence:

Claims that Epithalon has been "shown to extend human lifespan", the human data is encouraging but a long way short of that claim. Headlines about turning back biological age. Implications that the Khavinson research is equivalent to FDA-reviewed clinical evidence. The body of work is real and worth respecting; it's not the same kind of evidence as a Phase 3 trial.

Things to know if you're looking into it

  • How it's used in research: typically a small subcutaneous injection, often given in cycles (10-day or 20-day courses one to a few times per year). Some research-community protocols use a nasal spray or oral form, with less established bioavailability.
  • Cycle-based use: the standard pattern in published Russian research is short courses repeated over time, not continuous daily use.
  • Regulatory status: not FDA-approved. Approved as a drug in Russia for limited indications. Not on the FDA Category 2 list as of 2026.
  • Pineal-axis effects: bedtime dosing is typical because the pineal gland is most active at night. People with sleep disorders or shift-work sleep patterns sometimes report stronger circadian effects than people without.
  • Reported tolerability: in published trials and community use, side effects are generally mild and uncommon. Long-term safety data is limited.
  • Healthcare provider involvement: recommended for anyone considering use, especially in combination with other peptides or supplements.
  • Specific dosing protocols, mechanism, and the full reference list: all in the "Want to go deeper?" section below.

Reconstitution & dose calculator

Approved in Russia, not FDA-approved. All published clinical research comes from the Khavinson tradition in Russia; Western RCT replication is limited. Epithalon is run as short cycles, not continuous use — typically 10–20 day courses repeated 1–3 times per year. Higher doses don't improve results; once telomerase is activated, the peptide has done its job and additional dose doesn't keep activating it harder. This is an educational reference, not dosing guidance.
Suggested start
2 mg/day
For a 20-day course (40 mg total)
Common range
2–5 mg/day
10–20 day course, evening before bed
Max community dose
10 mg/day
Compressed 10-day protocol; not better, just shorter
Cycle
10–20 days
Repeated 1–3× per year, ~4 months between
mL
Defaults to 5 mg/mL (2 mL into the 10 mg vial), the standard community reconstitution. Epithalon doses are large (2–5 mg per injection), so going more dilute would push the higher doses past one syringe. The 5 mg/mL gives 40–100 syringe units across the common dose range.
mg
Subcutaneous injection, evening / before bed (aligns with pineal-axis activity). Once daily during the 10–20 day cycle, then off for several months. This is cyclical, not continuous — daily dosing only during the active course.
Concentration
5.0 mg/mL
Per dose
0.40 mL
40 units on insulin syringe
Doses per vial
~5
~5 days of daily dosing — need ~2 vials for a 10-day cycle, ~4 for 20 days

How to think about Epithalon dosing — different from most peptides on this site

Epithalon is run as short bursts, not titrated. The standard pattern is "pick a daily dose and a cycle length, run it daily for the full course, then stop for several months." There's no "stay put vs. escalate within a cycle" framework here — you're either doing the cycle or you're not. Adjustments happen between cycles, not within them.

Three common cycle patterns, all with similar total exposure:

  • 2 mg/day × 20 days = 40 mg total (most-cited Khavinson-tradition protocol)
  • 5 mg/day × 20 days = 100 mg total (more aggressive, common in research-peptide circles)
  • 10 mg/day × 10 days = 100 mg total (compressed schedule; same cumulative dose as above in half the time)

Higher daily dose doesn't reliably produce better outcomes. The mechanism is telomerase activation, which behaves like a switch — once it's on, additional dose doesn't keep activating it harder. The dose-and-cycle math is more about getting enough exposure to flip the switch than about pushing the dose ceiling. If you want to be more aggressive, the more defensible move is more frequent cycles (3×/year vs. 1×/year) rather than higher daily dose during a cycle.

Run the course in the evening, before bed. Epithalon's pineal-axis effects (melatonin signaling, circadian regulation) are stronger when timing matches the body's natural pineal activity, which peaks at night. People with sleep disorders or shift-work sleep patterns often notice the circadian effects more than people without those issues.

Cycle off for at least 4 months between courses. Russian protocols typically space cycles 4–6 months apart and run 1–3 cycles per year. Continuous or back-to-back courses aren't validated and undercut the cyclic logic the published research is based on.

Watch for: mild sleep changes (often welcome — this is the pineal/melatonin effect), occasional vivid dreams, rare reports of mood shifts. Side effects are uncommon in published trials and community use, but long-term safety data in healthy adults is limited.

The honest read. The basic biology — that Epithalon binds to and activates telomerase, and that telomere length tracks with cellular aging — is real and the Russian clinical record (over 30 years across multiple studies) is more substantial than most peptides on this site. The leap from "telomerase activation" to "extended healthspan in humans" is the real inferential gap. The Khavinson group's work hasn't been independently replicated by Western groups at the same scale, and what people experience subjectively (better sleep, more vivid dreams, sense of energy) is plausible but separable from the longevity claims that drive most of the marketing. If you're treating Epithalon as a longevity intervention, the strongest evidence is for the proxy markers; the outcome data isn't there yet.

For educational and research purposes only. This is not medical advice. Epithalon is approved as a drug in Russia for limited indications but is not FDA-approved. Most published clinical evidence comes from one research tradition (Khavinson, St. Petersburg Institute of Bioregulation and Gerontology); independent Western replication is limited. Consult a licensed healthcare provider before any health decision.

What people often ask

Does Epithalon actually extend life?

In animals, the published Russian studies show modest but consistent lifespan extension in several species. In humans, biomarker improvements have been reported in elderly populations, but no controlled trial has measured human longevity directly, which is incredibly hard to do. Anyone making confident "yes" claims about human lifespan is overreaching.

Does it really activate telomerase?

Cell-culture studies from the Khavinson group have reported telomerase activation in human cells. The mechanism isn't fully understood. Independent replication outside the original research group is limited.

Why isn't it FDA-approved?

Almost all the clinical data was generated under Russian regulatory frameworks, which don't directly translate to FDA approval. No Western pharmaceutical company has pursued Epithalon for FDA development, partly because of the regulatory hurdle and partly because the commercial case for a four-amino-acid peptide that's already widely available is unusual.

What's the difference between Epithalon and Epitalon?

They're spellings of the same peptide. "Epitalon" is closer to the Russian transliteration; "Epithalon" is the more common Western spelling. Same molecule (Ala-Glu-Asp-Gly).

Is it taken continuously or in cycles?

The published Russian research uses short cycles, typically 10-day or 20-day courses, repeated 1 to 2 times per year. That's the standard pattern in the literature, though research-community protocols vary.

How does it affect sleep?

The pineal-gland origin links it to melatonin and circadian-rhythm research. Russian trials have reported improved sleep quality and more youthful melatonin secretion patterns in elderly patients. Anecdotally, some people report better sleep within days of starting.

Are there side effects?

Reported side effects in published research and community reports are generally mild and uncommon: occasional injection-site reactions, mild fatigue, and rare reports of altered sleep on first use. Long-term safety in healthy adults using continuous protocols is not characterized.

FDA and regulatory status

Status as of May 5, 2026: Not FDA-approved for any medical indication. Approved in Russia for limited geriatric indications under a national framework that doesn't directly translate to FDA approval. Not currently on the FDA Category 2 list. No Phase II or Phase III trials are registered on ClinicalTrials.gov as of this date. Status updates land here when they happen.

Want to go deeper? Mechanism, dosing, half-life, the Khavinson research program, side effects, and references. Click to expand.

Background and discovery

Epithalon (also spelled Epitalon) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly. It was developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, derived from research on Epithalamin, a complex polypeptide preparation extracted from bovine pineal glands and studied since the 1970s as a "geroprotector." Epithalon represents the active synthetic short sequence identified within Epithalamin.

Mechanism of action

Telomerase activation

In-vitro studies report that Epithalon can induce telomerase activity in human somatic cells, including dividing cell populations that normally lack telomerase. The peptide may bind to telomerase regulatory regions or modulate transcription of telomerase components (TERT). Mechanism details remain incompletely characterized.

Pineal axis modulation

Given Epithalon's origin from pineal extract, the peptide is theorized to influence pineal function and melatonin secretion. Studies in elderly patients have reported normalization of nocturnal melatonin patterns.

Antioxidant and gene-expression effects

Some preclinical work reports antioxidant activity and effects on gene expression patterns associated with cellular aging, including reduced oxidative damage to DNA.

Commonly studied dosing protocols

These are not recommendations. Always consult a licensed healthcare provider before any clinical decision.

Subcutaneous (research range): 5 to 10 mg per dose, given once daily for 10 to 20 days, repeated 1 to 2 times per year. This cycle-based pattern reflects the standard Russian research protocols.

Timing: evening or bedtime dosing is typical, aligning with the pineal-active phase of the circadian cycle.

Treatment duration: short cycles repeated periodically, rather than continuous daily use, dominates the published literature.

Half-life and pharmacokinetics

Epithalon's plasma half-life is short, likely on the order of minutes to perhaps an hour after subcutaneous injection. The relatively short half-life is consistent with the cycle-based dosing model rather than continuous daily use.

Side effects and safety profile

Reported in published research and community use:

  • Mild injection-site reactions (uncommon, transient)
  • Initial sleep disturbances during first cycle (uncommon)
  • Fatigue or lethargy (uncommon)

Long-term safety in healthy adults using repeated cycles has not been formally characterized. Theoretical concerns about telomerase activation and cancer biology exist, uncontrolled telomerase activity is a feature of cancer cells, but Russian studies have not reported increased cancer incidence in treated populations. Independent verification of that observation is limited.

References

  1. Khavinson VK, Bondarev IE, Butyugov AA. (2003). "Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells." Bull Exp Biol Med, 135(6), 590–592. PubMed
  2. Khavinson VK, Anisimov VN. (2002). "20-year study of the effects of pineal peptide preparation: Epithalamin." Biogerontology, 3, 351–353. PubMed
  3. Anisimov VN, Khavinson VK, Provinciali M, et al. (2002). "Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice." Int J Cancer, 101(1), 7–10. PubMed
  4. Khavinson VK, Korkushko OV, Shatilo VB. (2010). "Effect of bioregulatory peptide preparations on the immune system of elderly people." Adv Gerontol, 23(3), 416–422. PubMed
  5. Korkushko OV, Khavinson VK, Shatilo VB, Antonyuk-Shcheglova IA. (2007). "Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging." Bull Exp Biol Med, 144(4), 485–488. PubMed
  6. Khavinson VK. (2002). "Peptides and ageing." Neuroendocrinol Lett, 23(suppl 3), 11–144. PubMed
For educational and research purposes only. This is not medical advice. Epithalon is not FDA-approved. Most published clinical evidence comes from one Russian research group; independent replication outside that institute is limited. Consult a licensed healthcare provider before considering any peptide. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does.